(Q42134477)

17 October 2017

title

Potency and specificity of CGS-16949A as an aromatase inhibitor (English)

1 reference

17 October 2017

Santen RJ

1

1 reference

17 October 2017

Langecker P

2

1 reference

17 October 2017

Santner SJ

3

1 reference

17 October 2017

Sikka S

4

1 reference

17 October 2017

Rajfer J

5

1 reference

17 October 2017

Swerdloff R

6

1 reference

17 October 2017

publication date

1 January 1990

1 reference

17 October 2017

1 reference

17 October 2017

volume

16

1 reference

17 October 2017

issue

1

1 reference

17 October 2017

page(s)

77-91

1 reference

Aminoglutethimide: review of pharmacology and clinical use.

17 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07435809009035921

In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07435809009035921

Estrogens and benign prostatic hyperplasia: the basis for aromatase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07435809009035921

The endocrine effects of ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07435809009035921

Inhibition of aromatase with CGS 16949A in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07435809009035921

Additive effects of aminoglutethimide, testololactone, and 4-hydroxyandrostenedione as inhibitors of aromatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07435809009035921

10.1080/07435809009035921

21 January 2018

Identifiers

DOI

1 reference

17 October 2017

1 reference